United States

AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

13 Jan 2017
Change (% chg)

$0.05 (+1.79%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

AcelRx Pharmaceuticals Inc appoints Interim CEO and restructured work force
Friday, 20 Mar 2015 03:00pm EDT 

AcelRx Pharmaceuticals Inc:Appoints Howard B. Rosen as interim Chief Executive Officer of AcelRx, effective April 1.Restructured its work force as part of a plan to reduce operating costs and focus the Company's financial and development resources on working with the U.S. Food and Drug Administration (FDA) to seek marketing approval for Zalviso, as well as to continue the development of ARX-04.Says this restructuring will reduce the Company's workforce by 19 employees, or about 36 pct of its employee work force, and primarily impacts the commercial team and field-based medical personnel, who were hired in preparation for a potential commercial launch of Zalviso.  Full Article

AcelRx Pharmaceuticals announces initiation of pivotal Phase 3 Trial For ARX-04
Monday, 16 Mar 2015 07:00am EDT 

AcelRx Pharmaceuticals Inc:Says dosing of the first patient in the pivotal Phase 3 study of ARX-04. ARX-04 is a non-invasive, single-use 30 mcg sufentanil sublingual tablet in a disposable, pre-filled, single-dose applicator.  Full Article

BRIEF-Acelrx Pharma says amended loan and security deal with Hercules Tech II and Hercules Capital Inc

* Among other things, amendment extends interest-only period from October 1, 2016 to April 1, 2017 - SEC filing